U.S. Markets closed

uniQure N.V. (QURE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
47.25+0.75 (+1.61%)
At close: 1:00PM EST
Sign in to post a message.
  • h
    harry
    something happening this weekend?
  • R
    Roger
    Will go up in the coming weeks!
    Bullish
  • P
    Paz
    Complete lack of interest in this stock now. I'll wait.
  • T
    Threlfall
    I started following "lionstock-aletrs” (Gooogle it - off course without any space or dash in between the words) and their notifications are better than anyone else.
  • E
    Erectosaurus
    Can someone tell me what management is paid to do here? It's just a complete pipeline puke.
  • Y
    Yahoo Finance Insights
    uniQure reached a 52 Week low at 35.40
  • B
    B
    Buyout?
  • E
    Edward
    I woke up this morning and I see QURE up 17% in pre market trading. I see NO news. The CEO is speaking today at the Piper Jaffray Healthcare Conference at 8:30 AM. I guess people are anticipating something great being announced today. Probably positive news about on going clinical trials.
    Bullish
  • E
    Edward
    I do not like seeing the 5% drop today. I guess that I was wrong about the stock trading in the 70’s until QURE gets bought. The stock is down because no big news came out at the J.P. Morgan Healthcare Conference. Investors are in the stock because they see QURE getting acquired and a premium being paid for the company. If they do not announce an acquisition by the Spring, I see a drop into the 50’s
  • E
    Edward
    This post will get a lot of hate but I speak the truth. uniQure was down 7.65% today and the market cap is now 2.95 billion, which is still above the enterprise value of the company. The RSI is now 46 and still showing overbought conditions. As I have stated before, I think that the stock will trade in the 70’s until uniQure gets bought. The buyout price will probably be in the $100-$120 range, which is a big premium to the enterprise value. A lot of privately held gene therapy companies and publicly traded gene therapy companies have been bought in recent years for less than the current market cap of uniQure. uniQure will get bought for around the same price as Spark Therapeutics, maybe a little higher, but it is crazy to think that uniQure will get bought for more than 4-5 billion
  • P
    Paz
    Wells reiterated outperform and raised price target from 65 to 90.
  • P
    Paz
    Now that AveXis and Spark have been acquired, Uniqure is the only public company left with an AAV-based gene therapy asset, which has both Breakthrough Therapy and PRIME designations. You could see more than one suitor for this company in the next few months.
  • b
    bocamp1
    Sure looks like something is cooking for this weekend. Biotech index down and equity here is strong and almost recouped all that unjustified loss from the other day. Also, good volume for the first time in the June calls.
  • h
    hilla
    Goldman Sachs just set a BUY and $98 target, and Cowen just set an OUTPERFORM.
  • S
    Speedy
    Big decline on high volume. No news I know.
  • b
    bocamp1
    Moody’s; Nova seems most likely.

    Companies use acquisitions to bring new growth drivers into the product portfolio or the pipeline, and to diversify away from blockbuster drugs that face patent expirations," Moody's senior vice president Michael Levesque wrote.

    The four biopharmaceutical companies are especially well-positioned as potential acquirers, thanks to generous cash levels and "moderate" debt-to-earnings ratios, according to the report. Shares of Amgen(AMGN) gained 0.3% in afternoon trading, Biogen(BIIB) tacked on 0.3% and Gilead(GILD) rose 0.9%, while Novo Nordisk(NOVO-B.KO) fell 1.4%.

    Bristol-Myers Squibb Co. (BMY) also has a "very high" capacity for M&A as a stand-alone company, but that will change following its acquisition of Celgene Corp. (CELG) , Moody's said.

    Other potential buyers with more limited M&A capacity include Allergan Plc (AGN) , AstraZeneca Plc (AZN.LN) , GlaxoSmithKline Plc (GSK.LN) , Mylan N.V. (MYL) and Takeda Pharmaceutical Company (4502.TO) -- companies with lower cash levels and higher debt-to-earnings ratios, the report said.

    Moody thinks any acquisitions will remain in the oncology and gene therapy space, mirroring recent moves like Eli Lilly & Co's (LLY) acquisition of Loxo Oncology and Biogen's acquisition of Nightstar Therapeutics. Roche Holding AG (ROG.EB) said in February it would acquire Spark Therapeutics, and Merck & Co Inc. (MRK) said earlier this week that it would buy cancer-treatment biotech Tilos Therapeutics (http://www.marketwatch.com/story/merck-to-buy-cancer-treatment-biotech-tilos-therapeutics-for-up-to-773-million-2019-06-10) in a deal that could be valued at up to $773 million.
    Merck & Co. Inc. said Monday it was buying privately held biopharmaceutical company Tilos Therapeutics, in a deal that could be valued at up to $773...
    Merck & Co. Inc. said Monday it was buying privately held biopharmaceutical company Tilos Therapeutics, in a deal that could be valued at up to $773...
    www.marketwatch.com
  • E
    Edward
    I love all the people on Yahoo finance who give thumbs down for every post no matter how logical the post is. These people only want posts saying that uniQure’s stock price should be $200.00. I just laugh at these people and can not wait to see how many thumbs down this post gets. uniQure has a market cap of 3 billion and an enterprise value 2.5 billion. Enterprise value is a way that a company values another company when they consider acquiring it. I would love to see a huge buyout of uniQure at a much higher price than $70.00 but I seriously question how much of a premium will be paid for uniQure as things stand today. I think that the stock will trade in the 70’s until uniQure gets bought. The buyout price will probably be in the $100-$110 range, which is a big premium to the enterprise value, but the acquiring company will have to pay up to get into the gene therapy space, which will cure a lot of rare diseases in the future.
  • [
    [A Blah's Blah]
    Buyout rumors is what keeps $QURE investors hanging, and helps execs cash in lucrative options
  • g
    gore
    I started following "awesomestokcalerts" (Gooogle it - off course without any space or dash in between the words) and their notifications are better than anyone else.
  • s
    stocktargetadvisor
    $QURE
    Downgrades Mizuho Securities Neutral USD 90 » USD 61
    Downgraded by Robert W Baird Outperform » Neutral USD 58
    Downgraded by Wells Fargo Overweight » Equal Weight USD 56
    Target Lowered by HC Wainwright Buy USD 73 » USD 64
    Target Lowered by Chardan Capital Buy USD 105 » USD 80
    Target Lowered by Stifel Nicolaus Buy USD 86 » USD 78